The Chemours Company filings document formal disclosures for a NYSE-listed global chemistry company with businesses in Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials. Recent Form 8-K reports furnish operating results and financial condition updates, including segment commentary on Opteon refrigerants, TiO2 pigment, and other specialty-chemistry markets.
Regulatory filings also cover capital-structure actions, including senior unsecured notes, indentures, guarantees, and redemption of outstanding debt. Definitive proxy materials document board structure, director elections, advisory compensation votes, auditor ratification, equity-incentive plan approval, and other shareholder voting matters.
Chemours (CC) reported third-quarter 2026 net sales of $1,540 million, compared with $1,495 million a year earlier, and net income attributable to Chemours of $196 million, versus $46 million. The company said third-quarter selling, general and administrative expense included $150 million received related to the PFAS Insurance MOU; other income, net, was $51 million, compared with $16 million.
For the first nine months of 2026, net sales were $4,512 million versus $4,478 million, and net loss attributable to Chemours was $107 million versus $339 million. Cash provided by operating activities was $263 million, compared with $127 million, while proceeds from sales of assets and businesses were $342 million versus $7 million. At September 30, 2026, unrestricted cash was $698 million, revolving-credit availability was $953 million and current liabilities were $1,777 million. Chemours said it believes it has sufficient liquidity to settle current liabilities through at least the end of November 2027; it also said an adverse resolution of legal or environmental matters could have a material adverse effect on liquidity.
Chemours (CC) amended its 2025 annual report to include Management’s Report on Internal Control over Financial Reporting, which was omitted from the original report because of an administrative error. The CEO and CFO concluded that disclosure controls and procedures were not effective at the reasonable assurance level as of December 31, 2025; the company says this ineffectiveness continued until the third quarter of 2026.
Management concluded that internal control over financial reporting was effective as of December 31, 2025, and PricewaterhouseCoopers’ report in the original annual report expressed an unqualified opinion on its effectiveness. During the third quarter of 2026, management implemented additional review procedures for completeness of non-financial statement disclosures. The amendment does not affect the consolidated financial statements.
The Chemours Company reported Q3 2026 net sales of $1.54 billion, up 3% year over year. Net income attributable to Chemours was $196 million versus $46 million, and included a $150 million receipt related to the PFAS insurance proceeds MOU. Adjusted net income was $31 million, up 19%, while Adjusted EBITDA reached $200 million, up 6%.
Results varied by segment: TSS sales fell 9% to $510 million and Adjusted EBITDA fell 30% to $136 million. Titanium Technologies sales rose 11% to $680 million, with Adjusted EBITDA of $85 million versus $25 million; Advanced Performance Materials sales rose 8% to $337 million and Adjusted EBITDA rose 71% to $24 million. Operating cash flow was $149 million and free cash flow was $98 million.
For Q4 2026, the company expects sequential net sales to decline 5% to 10% and Adjusted EBITDA of $160 million to $185 million. For full-year 2026, it expects sales growth of approximately 2% over 2025 and Adjusted EBITDA of $775 million to $800 million; net leverage is expected below 4.2x. It completed the Kuan Yin property sale for approximately $340 million net consideration, including $56 million gross proceeds for the remaining parcel.
Chemours Co director Courtney Mather acquired 2,118 deferred stock units on September 30, 2026, at a reported price of $13.57 per share. Each unit is the economic equivalent of one share of Chemours common stock and becomes payable in the first month following Mather’s termination of service as a director. Her reported resulting position was 11,147.0456 units, including deferred stock units and dividend equivalent units.
Chemours Co (CC) entered into a Settlement Agreement with the State of North Carolina and 11 local entities to resolve claims relating to PFAS and other emissions from its Fayetteville Works facility, as well as certain PFAS contamination elsewhere in the state, including from aqueous film-forming foam. The agreement calls for aggregate payments of $455 million over 15 years, beginning within 30 days of execution, and remains subject to court orders dismissing the covered claims. Under existing cost-sharing arrangements, Chemours will bear 50% of the settlement payments, with DuPont and Corteva sharing the remaining 50%. Chemours states its approximately $180 million net present value share is covered by existing accruals, and expects about $50 million of payments in the next twelve months. The Settlement Amount will count as about $210 million of qualified spend under the parties’ $4 billion MOU cap, and combined with a 2025 New Jersey settlement eliminates the need for further contributions to the MOU escrow account, including Chemours’ $50 million contribution previously due in September 2026.
Chemours Co (CC) furnished an investor presentation outlining its strategy, segment performance and capital structure as of the second quarter of 2026. For Q2 2026, the company generated $1.59 billion in net sales and $247 million in Adjusted EBITDA, but recorded a net loss attributable to Chemours of $274 million. Adjusted EPS was $0.42, while free cash flow reached $114 million, a 128% year‑over‑year increase, with 46% free cash flow conversion.
The presentation details the “Pathway to Thrive” plan targeting more than $250 million of cost reductions from 2024–2027, 5%+ sales CAGR and long‑term net leverage below 3.0x. Trailing twelve‑month net sales were $5.80 billion with Adjusted EBITDA of $733 million, including Titanium Technologies net sales of $2.39 billion and Adjusted EBITDA of $725 million at a 34% margin.
Chemours highlights growth in low‑GWP Opteon refrigerants, data center and semiconductor applications, and a mid‑cycle Adjusted EBITDA floor target of $400 million for Titanium Technologies. The company reports gross debt of $3.9 billion, net debt of $3.2 billion, and Q2 2026 net leverage of 4.4x, supported by €230 million of recent term‑loan repayment and approximately $287 million initial net proceeds from the Kuan Yin site sale, while continuing to resolve legacy environmental and PFAS‑related matters through settlements and mitigation commitments.
Chemours Co Chief Accounting Officer David Will reported a Form 4 transaction involving 2,426 shares of common stock on August 12, 2026. These shares were automatically withheld to satisfy tax obligations upon vesting of restricted stock units and related dividend equivalent units, at a value of $15.24 per share. The filing specifies that no shares were sold in the open market. Following this tax-withholding disposition, Will’s holdings, including directly owned shares, restricted stock units, and dividend equivalent units, total 30,868.097 shares.
Chemours Co executive Gerardo Familiar Calderon, President of Advanced Performance Materials, purchased 1,935 shares of Common Stock on August 12, 2026 at $15.53 per share in an open-market or private transaction. Following this transaction, his directly owned and equity-based holdings total 58,547.3746 shares, which include directly owned shares, restricted stock units, and dividend equivalent units, and reflect an adjustment correcting an administrative error in prior reports.
Chemours Co Chief Executive Officer and director Denise Dignam purchased 3,378 shares of Chemours common stock on 2026-08-11 at $14.95 per share in an open-market transaction. Following this trade, she directly owns a total of 339,916.3423 shares, which includes directly owned shares, restricted stock units and dividend equivalent units, with the total adjusted to correct an administrative error in prior reports.
Chemours Co executive Michael Robert Foley, President of Titanium Technologies, purchased 1,934.2313 shares of common stock on August 7, 2026 in an open-market transaction at a weighted average price of $15.51 per share, with individual trade prices ranging from $15.51 to $15.54.